Shares of Celyad SA (NASDAQ:CYAD) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating. Celyad SA’s rating score has improved by 50% from three months ago as a result of various analysts’ ratings changes.

Analysts have set a one year consensus price target of $49.00 for the company, according to Zacks. Zacks has also given Celyad SA an industry rank of 107 out of 265 based on the ratings given to related companies.

CYAD has been the subject of several analyst reports. ValuEngine raised Celyad SA from a “sell” rating to a “hold” rating in a research note on Thursday, June 29th. BidaskClub downgraded Celyad SA from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $49.00 price objective (up from $35.00) on shares of Celyad SA in a research note on Friday, September 1st.

ILLEGAL ACTIVITY NOTICE: “Zacks: Celyad SA (CYAD) Receives Average Rating of “Strong Buy” from Analysts” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/24/zacks-celyad-sa-cyad-receives-average-rating-of-strong-buy-from-analysts.html.

Celyad SA (NASDAQ CYAD) opened at 57.30 on Friday. The company’s 50-day moving average price is $52.38 and its 200 day moving average price is $52.38. Celyad SA has a 12 month low of $16.31 and a 12 month high of $57.30. The stock’s market capitalization is $545.78 million.

An institutional investor recently raised its position in Celyad SA stock. Victory Capital Management Inc. lifted its holdings in shares of Celyad SA (NASDAQ:CYAD) by 6.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 374,493 shares of the company’s stock after buying an additional 22,600 shares during the period. Victory Capital Management Inc. owned about 3.93% of Celyad SA worth $9,988,000 at the end of the most recent reporting period. Institutional investors own 4.06% of the company’s stock.

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Get a free copy of the Zacks research report on Celyad SA (CYAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.